Philip Lee Miller, MD, Editor in Chief
Philip Lee Miller, MD • Advanced Oncology Protocols — Part 2 Intermittent ADT and The Resistance ParadoxWhy “Cycling” Testosterone values is the key to preventing castrate-resistant disease. A critical look at IAD, BAT, and the PROMISE TNM convention.
Published January 14, 2026 | Part 2 of the ADT SeriesIn This ...
Philip Lee Miller, MD, Editor in Chief
Philip Lee Miller, MD • Clinical Insights The Hidden Crisis in ADT Prostate Cancer Care
A critical examination of the unfulfilled promise in preventing ADT Prostate Cancer induced osteoporosis and sarcopenia. An urgent call for a paradigm shift in clinical practice.
Published January 6, 2026 | Evidence-Based Medici...Philip Lee Miller, MD, Editor in Chief
Coagulation and Anticoagulatant TherapyPhilip Lee Miller, MD, Editor in Chief
The Estrone Paradox: Why “Total Estrogen” Is Misleading You (And Why Aromatase Inhibitors Fail)In my practice over the last three years, I have noticed a disturbing trend in lab results for both men and women: Estrone (E1) levels are rising.
Philip Lee Miller, MD, Editor in Chief
Cannabinoids in Cancer, Sleep, and Safety A deep dive into the Endocannabinoid System, the differences between CBD, CBG, and CBN, and critical safety protocols for high-dose therapy in cancer patients. Learn ...